Compare RVT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVT | IMCR |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | RVT | IMCR |
|---|---|---|
| Price | $16.48 | $36.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | 243.4K | ★ 292.7K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.95 | N/A |
| Revenue | N/A | ★ $379,590,000.00 |
| Revenue This Year | N/A | $32.31 |
| Revenue Next Year | N/A | $10.50 |
| P/E Ratio | $4.98 | ★ N/A |
| Revenue Growth | N/A | ★ 28.11 |
| 52 Week Low | $11.85 | $23.15 |
| 52 Week High | $14.93 | $40.72 |
| Indicator | RVT | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 63.60 | 48.80 |
| Support Level | $16.04 | $35.81 |
| Resistance Level | $16.26 | $40.71 |
| Average True Range (ATR) | 0.26 | 1.79 |
| MACD | 0.10 | -0.25 |
| Stochastic Oscillator | 92.86 | 16.80 |
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements. The company invests in Industrials, Financials, Information Technology, Materials, Health Care, Communication Services, Real Estate and others.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.